Weak expansion of sales channels? Leading synthetic biology company Huaheng Biological's net profit fell more than 20% in the first half of the year.
Due to increased competition and rising costs, Huaheng Biotech's net income for the first half of the year fell by 21.72%. It is stated that the sales channels for the core product L-Xeonine need to be further expanded, and market share needs to be increased. The registered and effective issuance plan of Huaheng Biotech has been registered and effective, but it is stated that if the project cannot generate benefits as expected or the actual income is lower than expected, there may be a risk of reduced profitability.
How is the market outlook for vitamins? Zhejiang Nhu's Q2 net profit of 1.335 billion yuan hit a record high|Interpretations of financial reports
①The vitamin bull market significantly boosts manufacturers' performance; ②zhejiang nhu's Q2 net profit hits a record high for the same period in history; ③The company benefits from a high proportion of overseas business; ④The increase in the third quarter expands, further benefiting manufacturers.
Due to lower caffeine prices, CSPC Innovation Pharmaceutical's Q2 performance continued the downward trend from Q1. | Interpretations
Due to factors such as the decrease in caffeine prices, both revenue and net income of cspc innovation pharmaceutical have declined. Several pipelines of cspc innovation pharmaceutical have made progress, and Enrulizumab has been conditionally approved for listing in June of this year. In order to improve the industrialization capabilities of monoclonal antibodies and ADCs, the company announced that BSP will invest in the construction of two production line projects.
Yifan Pharmaceutical's H1 revenue and net profit both increased, and innovative drug Yilishu cumulative shipments exceeded 1.1 million units. | Interpretations
① Thanks to a sharp increase in domestic pharmaceutical product revenue and sales of vitamin B5 series products, H0.1 billion Pharm's revenue and net profit increased this year. ② The gross margin of APIs decreased year-on-year. Yifan Pharmaceutical said that the price of the company's vitamin B5 products is still running low. ③ The company's construction of the Hangzhou Synthetic Biology Industrial Park is being accelerated.
Breaking news! Small market cap oil & gas concept stocks will pay back tax of 0.48 billion yuan | Summary of after-hours announcements.
Minsheng Health plans to sign a strategic cooperation agreement in the probiotics field.
Northbound capital large buy report: Zhejiang NHU received net sell of 0.254 billion yuan.
On August 9th, northbound funds sold a net total of 7.765 billion yuan throughout the day.